Want to see AU:VIT full AI Analyst Report?
VIT Stock Chart & Stats
AU$0.03
>-AU$0.01(-6.67%)
At close: 4:00 PM EDT
AU$0.03
>-AU$0.01(-6.67%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume435.95K
Average Volume (3M)228.84K
Market Cap
AU$17.23M
Enterprise ValueAU$49.17
Total Cash (Recent Filing)AU$6.10M
Total Debt (Recent Filing)AU$17.34M
Price to Earnings (P/E)21.7
Beta1.50
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.69%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding662,741,800
10 Day Avg. Volume238,134
30 Day Avg. Volume228,844
Financial Highlights & Ratios
PEG Ratio-1.00
Price to Book (P/B)0.78
Price to Sales (P/S)0.30
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureThe company’s low debt-to-equity (0.25) and high equity ratio (63.85%) create a conservative capital structure. This reduces refinancing and solvency risk, supports resilience through regulatory or market cycles, and preserves capacity to fund strategic investments or compliance without excess leverage.
Stable Gross MarginsA gross profit margin near 27.21% shows the business retains a meaningful portion of revenue after direct costs. Sustained gross margins help absorb SG&A, support reinvestment in R&D and distribution, and provide a buffer if top-line volatility occurs, underpinning mid-term operational stability.
Positioned In Medicinal Cannabis SectorCronos Australia’s focus on medicinal cannabis and related healthcare products positions it in a structural growth market with expanding regulatory acceptance. That specialization supports durable demand, opportunities for product differentiation, and potential recurring, prescription-driven revenues over time.
Bears Say
Severe Free Cash Flow DeclineA free cash flow collapse of -2056% greatly reduces internal funding for operations, capex and shareholder returns. It forces reliance on external financing, increases liquidity and refinancing risk, and can materially constrain the company’s ability to execute long-term strategic plans or pursue growth opportunities.
Poor Cash ConversionAn operating cash flow to net income ratio of 0.14 indicates weak conversion of reported profits into cash. Persistent poor cash conversion can signal working-capital strains or significant non-cash charges, limiting internal funding capacity and increasing dependence on external capital for growth or to meet obligations.
Weak Revenue Trend And Low Operating EfficiencySlight negative revenue growth (-2.0%) combined with low EBIT/EBITDA margins signals limited operational leverage. Without consistent top-line expansion, fixed costs pressure profitability, hampering margin improvement and making it harder to achieve scale economies or reinvest for differentiation over the medium term.
Cronos Australia Ltd. News
VIT FAQ
What was Cronos Australia Ltd.’s price range in the past 12 months?
Cronos Australia Ltd. lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.
What is Cronos Australia Ltd.’s market cap?
Cronos Australia Ltd.’s market cap is AU$17.23M.
When is Cronos Australia Ltd.’s upcoming earnings report date?
Cronos Australia Ltd.’s upcoming earnings report date is Aug 26, 2026 which is in 20 days.
How were Cronos Australia Ltd.’s earnings last quarter?
Cronos Australia Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cronos Australia Ltd. overvalued?
According to Wall Street analysts Cronos Australia Ltd.’s price is currently Overvalued.
Does Cronos Australia Ltd. pay dividends?
Cronos Australia Ltd. pays a Notavailable dividend of AU$0.002 which represents an annual dividend yield of 7.69%. See more information on Cronos Australia Ltd. dividends here
What is Cronos Australia Ltd.’s EPS estimate?
Cronos Australia Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cronos Australia Ltd. have?
Cronos Australia Ltd. has 662,741,800 shares outstanding.
What happened to Cronos Australia Ltd.’s price movement after its last earnings report?
Cronos Australia Ltd. reported an EPS of -AU$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.167%.
Which hedge fund is a major shareholder of Cronos Australia Ltd.?
Currently, no hedge funds are holding shares in AU:VIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Australia Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.51%
12-Months-Change
Fundamentals
Return on Equity
7.69%
Trailing 12-Months
Asset Growth
8.56%
Trailing 12-Months
Company Description
Cronos Australia Ltd.
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. This entity was formerly recognized as Cronos Australia Limited before adopting the name Vitura Health Limited in February 2023.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―